2021 ASCO Annual Meeting to Feature New Outcomes Research from Analysis Group

June 4, 2021

Members of Analysis Group’s Health Care practice will present five poster presentations and seven online abstracts at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (June 4–8). The annual program will feature a program of educational and scientific sessions on cancer research, treatment, and patient care.

Poster presentations include:

• “Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States (U.S.),” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Wendy Cheng, and Analysts Sanjana Sundaresan and Lujia Zhang – in collaboration with teams from AstraZeneca and Merck & Co.
• “Disease-Free Survival as a Predictor of Overall Survival in Localized Renal Cell Carcinoma (RCC) following First Nephrectomy,” coauthored by an Analysis Group team – including Managing Principal James Signorovitch, Vice President Yan Song, Associate Su Zhang, and Senior Analysts Christopher Carley and JingJing Zhu – in collaboration with teams from the Perelman School of Medicine at the University of Pennsylvania and Merck & Co.
• “Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL),” coauthored by an Analysis Group team – including Vice President Hongbo Yang and Associate Cassie Tang – in collaboration with teams from the Penn Medicine Abramson Cancer Center and Novartis Pharmaceuticals.
• “Nivolumab versus placebo as adjuvant therapy for resected melanoma: a propensity-weighted indirect treatment comparison and number-needed-to-treat analysis for recurrence-free survival and overall survival,” coauthored by an Analysis Group team – including Vice President Keith Betts, Managers Ella Du and Yan Wang, Associate Yan Chen, and Analyst Travis Wang – in collaboration with teams from NYU Langone Health’s Perlmutter Cancer Center, Memorial Sloan Kettering Cancer Center, and Bristol Myers Squibb.
• “Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis,” coauthored by an Analysis Group team – including Vice President Hongbo Yang and Manager Wei Gao – in collaboration with teams from Cedars Sinai Medical Center, the Duke Cancer Institute, the Huntsman Cancer Center at the University of Utah, Pfizer, and Astellas Pharma.

Online abstracts include:

• “Tazemetostat (TAZ) in relapsed/refractory (R/R) follicular lymphoma (FL): Propensity-score matched analysis of E7438-G000-101 trial outcomes,” coauthored by an Analysis Group team – including Principal Dave Nellesen, Manager David Proudman, and Associate Deepshekhar Gupta – in collaboration with a team from Epizyme.
• “Health care cost impact associated with adverse events (AEs) among treatments in third-line+ (3L+) relapsed/refractory follicular lymphoma (R/R FL),” coauthored by an Analysis Group team – including Principal Dave Nellesen and Manager David Proudman – in collaboration with teams from the Moffitt Cancer Center, the Texas Oncology-Baylor Charles A. Sammons Cancer Center, and Epizyme.
• “Comprehensive genomic profiling in advanced/metastatic colorectal cancer: Number needed to test and budget impact of expanded first-line use,” coauthored by an Analysis Group team – including Managing Principal James Signorovitch and Manager David Proudman – in collaboration with teams from the Duke Cancer Center, Tempus, and the Dana-Farber Cancer Institute.
• “Treatment Response among Patients with Multiple Myeloma Initiating Daratumumab across Different Lines of Therapy: A Real-World Chart Review Study,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Marie-Hélène Lafeuille, and Manager Philippe Thompson-Leduc – in collaboration with teams from the Levine Cancer Institute, Weill Medical College of Cornell University, and Janssen.
• “Clinical pathways implementation in a community-based oncology practice: Real-world outcomes in patients with non-small cell lung cancer segmented by disease stage at diagnosis,” coauthored by an Analysis Group team – including Managers Debbie Goldschmidt and Marie Louise Edwards – in collaboration with teams from Tennessee Oncology, Varian Medical Systems, and Bristol Myers Squibb.
• “Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence,” coauthored by an Analysis Group team – including Vice President Hongbo Yang, Manager Cynthia Qi, and Associate Su Zhang – in collaboration with a team from Novartis Pharmaceuticals.
• “Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Marie-Hélène Lafeuille, Manager Bruno Émond, Senior Research Professional Isabelle Ghelerter, and Analyst Caterina Wu – in collaboration with a team from Washington University School of Medicine in St. Louis and GlaxoSmithKline.

Read more about the 2021 ASCO Annual Meeting